Sadanand Vodala

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

5h-index247citations26works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hemoglobinopathies and Related Disorders(17), Acute Myeloid Leukemia Research(12), Myeloproliferative Neoplasms: Diagnosis and Treatment(7), Iron Metabolism and Disorders(5), Erythrocyte Function and Pathophysiology(5)

Publications26 total

Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes
Journal of Clinical Investigation·2025· 2 citedOpen Access
Circulating immune cells exhibit distinct traits linked to metastatic burden in breast cancer
Breast Cancer Research·2025· 2 citedOpen Access
Additional file 2 of Circulating immune cells exhibit distinct traits linked to metastatic burden in breast cancer
Figshare·2025Open Access
Clonal Hematopoiesis-Related Mutations Are Associated with Favorable Clinical Benefit Following Luspatercept Treatment in Patients with Lower-Risk Myelodysplastic Syndromes: A Subgroup Analysis from the Phase 3 COMMANDS Trial
Blood·2023· 3 cited
GDF11/SMAD Regulated Splicing of <i>GATA1</i> Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Blood·2023Open Access
Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis- (MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study
Blood·2023· 1 cited
Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis
Blood·2023· 1 citedOpen Access
Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study
Blood·2023· 8 cited
Improvement of Underlying Disease Pathophysiology of Ineffective Erythropoiesis in Non-Transfusion-Dependent (NTD) Patients with β-Thalassemia Receiving Luspatercept: Biomarker Analysis from the BEYOND Trial
Blood·2023· 2 cited
Impact of Genomic Landscape and Mutational Burden on Primary Endpoint Responses in the COMMANDS Study
Blood·2023· 4 cited
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion‐dependent thalassemia
American Journal of Hematology·2023· 27 citedOpen Access
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
Leukemia·2023· 16 citedOpen Access
Splenic iron decreases without change in volume or liver parameters during luspatercept therapy
Blood·2023· 5 cited
MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
Clinical Lymphoma Myeloma & Leukemia·2023
POSTER: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
Clinical Lymphoma Myeloma & Leukemia·2023
Oral Abstract: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
Clinical Lymphoma Myeloma & Leukemia·2023Open Access
POSTER: MDS-071 Luspatercept Restores Effective Erythropoiesis and Provides Superior and Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase III COMMANDS Study
Clinical Lymphoma Myeloma & Leukemia·2023
MDS-071 Luspatercept Restores Effective Erythropoiesis and Provides Superior and Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase III COMMANDS Study
Clinical Lymphoma Myeloma & Leukemia·2023
P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY
HemaSphere·2023· 5 citedOpen Access
P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
HemaSphere·2023· 1 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Uwe Platzbecker(13), Sheida Hayati(13), Rajasekhar N.V.S. Suragani(10), Jeevan K. Shetty(9), Guillermo Garcia‐Manero(9), Amer M. Zeidan(8), Aarif Ahsan(8), Anita K. Gandhi(8), Rami S. Komrokji(7), Pierre Fenaux(7), Srinivas Aluri(7), Valeria Santini(6), Ana Carolina Giuseppi(6), Karen L. Keeperman(6), Shelonitda Rose(6), Matteo Giovanni Della Porta(5), Jake Shortt(5), David Valcárcel(5), Anna Jonášová(5), Sophie Dimicoli‐Salazar(5)